Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review

Table 13 Individual studies included for induction or maintenance of clinical response in ulcerative colitis

Study	Country	Intervention	Comparator	Study design	Follow-up	n	Clinical response
Arts et al[36]	Belgium	Cyclosporine	-	Retrospective cohort	9 d	86	83.7%1
Prieux-Klotz et al[37]	France	AZA or 6-MP	-	Retrospective cohort	38 mo	80	70%2
Yamamoto et al[38]	Japan	Tacrolimus	Anti-TNF	Retrospective	12 wk	100	62% (tacrolimus); 64% (anti-TNF); P > 0.993
Ogata et al[39]	Japan	Tacrolimus	Placebo	RCT	2 wk	62	50% (tacrolimus); 13.3% (placebo); P = 0.0034
Van Assche et al[48]	Belgium	Cyclosporine 4 mg/kg	Cyclosporine 2 mg/kg	RCT	2 wk	73	84.2% (4 mg/kg); 85.7% (2 mg/kg)5
Oshitani et al[47]	Japan	Prednisolone	Methylprednisolone	Retrospective cohort	7-14 d	71	82% (prednisolone); 82% (methylprednisolone)6

¹Response defined as colectomy avoided;^{. 2}Clinical response defined by a decrease in the partial Mayo score of at least 3 points and 30% with a rectal bleeding Mayo subscore ≤ 1;

³Clinical response was defined as a decrease of at least 2 points in the clinical section (stool frequency and/or rectal bleeding);

⁴Clinical response was defined as improvement in all Disease Activity Index subscores;

⁵Clinical response was defined as a score of less than 10 at day 8 with a drop of ≥ 3 as compared with baseline;

⁶Clinical response considered as at least one of: decreased blood in stools compared with previous findings; soft or normal stool; no nocturnal defecation. 6-MP: 6-mercaptopurine; AZA: Azathioprine; n: Number of patients; RCT: Randomized clinical trial; TNF: Tumor necrosis factor.